Bioxytran, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 2.46 million compared to USD 4.03 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.04 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.112 USD | +1.27% | +9.80% | -25.33% |
19/04 | Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
19/04 | Bioxytran, Inc. Announces Board Changes | CI |
1st Jan change | Capi. | |
---|---|---|
-25.33% | 19.35M | |
+4.84% | 109B | |
+11.38% | 105B | |
-0.38% | 22.25B | |
-12.20% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.85% | 16.85B | |
+4.54% | 13.76B | |
+35.18% | 12.46B |
- Stock Market
- Equities
- BIXT Stock
- News Bioxytran, Inc.
- Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022